Methods of using activin receptor type ii signaling inhibitors
AssigneeKeros Therapeutics, Inc.
InventorsJasbir S. SEEHRA, Jennifer Lachey, Christopher R. Rovaldi, Elissa Furutani
Life of this patent
Estimating the term…
Abstract
The invention features methods of treating a subject receiving a cytopenia-associated myelofibrosis treatment by co-administering an activin receptor type II (ActRII) signaling inhibitor. The ActRII signaling inhibitor may be an antibody that binds to an ActRII ligand, an ActRII antibody, or an ActRII ligand trap.
Claims52
A method of treating a subject having myelofibrosis, the method comprising the step of administering in combination to the subject an effective amount of a cytopenia-associated myelofibrosis treatment and an ActRII signaling inhibitor.
A method of treating a subject with a myelofibrosis that has been identified as having a cytopenia, the method comprising the step of administering in combination to the subject an effective amount of a cytopenia-associated myelofibrosis treatment and an ActRII signaling inhibitor.
A method of treating a cytopenia in a subject diagnosed as having myelofibrosis, the method comprising the step of administering in combination to the subject an effective amount of a cytopenia-associated myelofibrosis treatment and an ActRII signaling inhibitor.
A method of treating a subject having polycythemia vera, the method comprising the step of administering in combination to the subject an effective amount of a cytopenia-associated myelofibrosis treatment and an ActRII signaling inhibitor.
A method of treating a subject having steroid-refractory graft-versus-host disease, the method comprising the step of administering in combination to the subject an effective amount of a cytopenia-associated myelofibrosis treatment and an ActRII signaling inhibitor.
A method of treating a cytopenia in a subject diagnosed as having polycythemia vera, the method comprising the step of administering in combination to the subject an effective amount of a cytopenia-associated myelofibrosis treatment and an ActRII signaling inhibitor.
A method of treating a cytopenia in a subject diagnosed as having steroid-refractory graft-versus-host disease, the method comprising the step of administering in combination to the subject an effective amount of a cytopenia-associated myelofibrosis treatment and an ActRII signaling inhibitor.
A method of treating a subject receiving treatment with a cytopenia-associated myelofibrosis treatment, the method comprising the step of administering in combination to the subject an effective amount of a cytopenia-associated myelofibrosis treatment and an ActRII signaling inhibitor.
A method of improving adherence to treatment with a cytopenia-associated myelofibrosis treatment in a subject in need thereof, the method comprising the step of administering in combination the cytopenia-associated myelofibrosis treatment and an ActRII signaling inhibitor.
A method of increasing the dose of a cytopenia-associated myelofibrosis treatment administered to a subject in need thereof, the method comprising the step of administering in combination the cytopenia-associated myelofibrosis treatment and an ActRII signaling inhibitor.
A method of increasing treatment duration for a cytopenia-associated myelofibrosis treatment in a subject in need thereof, the method comprising the step of administering in combination the cytopenia-associated myelofibrosis treatment and an ActRII signaling inhibitor.
A method of maintaining dose intensity for a cytopenia-associated myelofibrosis treatment in a subject in need thereof, the method comprising the step of administering in combination the cytopenia-associated myelofibrosis treatment and an ActRII signaling inhibitor.
A method of decreasing episodes of cytopenia associated with a cytopenia-associated myelofibrosis treatment in a subject in need thereof, the method comprising the step of administering in combination the cytopenia-associated myelofibrosis treatment and an ActRII signaling inhibitor.
A method of decreasing transfusion burden in a subject treated with a cytopenia-associated myelofibrosis treatment, the method comprising the step of administering in combination the cytopenia-associated myelofibrosis treatment and an ActRII signaling inhibitor.
A method of decreasing bleeding events in a subject treated with a cytopenia-associated myelofibrosis treatment, the method comprising the step of administering in combination the cytopenia-associated myelofibrosis treatment and an ActRII signaling inhibitor.
A method of decreasing infections in a subject treated with a cytopenia-associated myelofibrosis treatment, the method comprising the step of administering in combination the cytopenia-associated myelofibrosis treatment and an ActRII signaling inhibitor.
A method of decreasing treatment interruptions or discontinuations for a cytopenia-associated myelofibrosis treatment in a subject in need thereof, the method comprising the step of administering in combination the cytopenia-associated myelofibrosis treatment and an ActRII signaling inhibitor.
A method of resuming treatment with a cytopenia-associated myelofibrosis treatment in a subject who developed a myelofibrosis treatment-associated cytopenia, the method comprising the step of administering in combination the cytopenia-associated myelofibrosis treatment and an ActRII signaling inhibitor.
Dependencies are inferred from the claim text.